Home Cart Sign in  
Chemical Structure| 1219810-16-8 Chemical Structure| 1219810-16-8

Structure of RSL3
CAS No.: 1219810-16-8

Chemical Structure| 1219810-16-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

RSL3 ((1S,3R)-RSL3) is an inhibitor of glutathione peroxidase 4 (GPX4), which reduces GPX4 expression and induces ferroptosis in head and neck cancer cells. In HN3 resistant cells, it increases the protein levels of p62 and Nrf2, leading to Keap1 inactivation.

Synonyms: (1S,3R)-RSL3

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations      Show More

Li, Donglin ; Li, Yingping ; Chen, Liangjie ; Gao, Chengchang ; Dai, Bolei ; Yu, Wenjia , et al.

Abstract: The natural product auraptene can influence tumor cell proliferation and invasion, but its effect on hepatocellular carcinoma (HCC) cells is unknown. Here, we report that auraptene can exert anti-tumor effects in HCC cells via inhibition of cell proliferation and ferroptosis induction. Auraptene treatment induces total ROS and lipid ROS production in HCC cells to initiate ferroptosis. The cell death or cell growth inhibition of HCC cells induced by auraptene can be eliminated by the ROS scavenger NAC or GSH and ferroptosis inhibitor ferrostatin-1 or Deferoxamine Mesylate (DFO). Mechanistically, the key ferroptosis defense protein SLC7A11 is targeted for ubiquitin–proteasomal degradation by auraptene, resulting in ferroptosis of HCC cells. Importantly, low doses of auraptene can sensitize HCC cells to ferroptosis induced by RSL3 and cystine deprivation. These findings demonstrate a critical mechanism by which auraptene exhibits anti-HCC effects via ferroptosis induction and provides a possible therapeutic strategy for HCC by using auraptene or in combination with other ferroptosis inducers.

Keywords: auraptene ; HCC ; ferroptosis ; SLC7A11

Purchased from AmBeed:

Yang, Haoying ; Dai, Bolei ; Chen, Liangjie ; Li, Yingping ; Jin, Xiaorui ; Gao, Chengchang , et al.

Abstract: Ferroptosis, a recently elucidated style of regulated cell death, has emerged as a significant area of investigation in cancer biology. Natural active compounds that have anti-cancer effects are promising candidates for cancer prevention. Iberverin, a natural compound derived from Brassica oleracea var. capitata, has been shown to exert anti-tumor activities in some cancers. However, its role in hepatocellular carcinoma (HCC) cells and the molecular mechanisms are still poorly understood. In this study, we proved that iberverin can induce intracellular reactive oxygen species (ROS) generation to inhibit cell proliferation and initiate ferroptotic cell death in HCC cells, which can be eradicated by the ferroptosis inhibitor ferrostatin-1 (Fer-1) or deferoxamine mesylate (DFO) and ROS scavenger (GSH or NAC). Mechanistically, iberverin treatment can simultaneously downregulate SLC7A11 mRNA level and degrade GPX4 through the ubiquitination pathway, leading to lipid peroxidation and ferroptotic cell death in HCC cells. Significantly, a low dose of iberverin can remarkably increase the sensitivity of HCC cells to ferroptosis induced by canonical ferroptosis inducers RSL3 and imidazole ketone erastin (IKE). This study uncovers a critical function of iberverin in preventing HCC through ferroptosis and provides a promising strategy for HCC treatment either via iberverin alone or in combination with canonical ferroptosis inducers in the future.

Keywords: iberverin ; HCC ; ferroptosis ; GPX4 ; SLC7A11

Purchased from AmBeed:

Bian, Xueli ; Yu, Wenjia ; Li, Yingping ; Gao, Chengchang ; Dai, Bolei ; Yang, Haoying , et al.

Abstract: The crosstalk between tumor progression and ferroptosis is largely unknown. Here, we identify malate dehydrogenase 2 (MDH2) as a key regulator of ferroptosis. MDH2 deficiency inhibits hepatocellular carcinoma (HCC) cell growth and promotes sensitivity of HCC cells to RSL3-induced ferroptosis. MDH2 knockdown enhances RSL3-induced intracellular reactive oxygen species (ROS), free iron ions and lipid peroxides levels, leading to HCC ferroptotic cell death which is rescued by Ferrostatin-1 and iron chelator Deferiprone. Importantly, inhibition of HCC cell growth caused by MDH2 deficiency is partially rescued by ferroptosis blockade. Mechanistically, MDH2 resists RSL3-induced ferroptosis sensitivity by dependence on GPX4, which is stabilized by MDH2 in HCC. The protein expression of MDH2 and GPX4 is positively correlated with each other in HCC cell lines. Furthermore, The Cancer Genome Atlas (TCGA) database shows that MDH2 and GPX4 are highly expressed in HCC samples, their expression is positively correlated with HCC stages, and GPX4 expression is associated with poor prognosis of HCC patients. These findings reveal a critical mechanism by which HCC evades ferroptosis via MDH2-mediated stabilization of GPX4 to promote tumor progression and underscore the potential of MDH2 inhibition in combination with ferroptosis inducers for the treatment of HCC.

Keywords: Tumor progression ; ferroptosis ; MDH2 ; HCC

Purchased from AmBeed:

Alternative Products

Product Details of RSL3

CAS No. :1219810-16-8
Formula : C23H21ClN2O5
M.W : 440.88
SMILES Code : O=C([C@H]1CC2=C([C@H](C3=CC=C(C(OC)=O)C=C3)N1C(CCl)=O)NC4=C2C=CC=C4)OC
Synonyms :
(1S,3R)-RSL3
MDL No. :MFCD30187526
InChI Key :TXJZRSRTYPUYRW-NQIIRXRSSA-N
Pubchem ID :1750826

Safety of RSL3

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HT22 mouse hippocampal neuronal cells 80 nM 24 hours To evaluate the protective effect of catechol estrogens against erastin/RSL3-induced ferroptosis. Results showed that four catechol estrogens (2-OH-E1, 2-OH-E2, 4-OH-E1, and 4-OH-E2) significantly inhibited erastin/RSL3-induced cell death and reduced the accumulation of NO, ROS, and lipid-ROS. Sci Rep. 2024 Oct 14;14(1):23988.
Pfa1 Gpx4-KO cells 300 nM 24 hours To assess the sensitivity of FSP1 mutants to ferroptosis Nat Struct Mol Biol. 2023 Nov;30(11):1806-1815.
Pfa1 cells 500 nM 2 days To identify possible mutations affecting FSP1's ferroptosis-suppressive function Nat Struct Mol Biol. 2023 Nov;30(11):1806-1815.
synovial fibroblasts 0.125 μM 12 hours Evaluate the effect of RSL3 on ferroptosis in synovial fibroblasts, results showed RSL3 induced cell death and lipid peroxidation Nat Commun. 2022 Feb 3;13(1):676
C4-2 0.5 μM 9 days To evaluate the effect of RSL3 on prostate cancer cell colony formation, results showed that RSL3 significantly inhibited colony formation of prostate cancer cells. Cancer Res. 2021 Mar 15;81(6):1583-1594.
PC3 0.125, 0.25, 0.5 μM 72 h To evaluate the effect of RSL3 on prostate cancer cell growth, results showed that all prostate cancer cell lines were sensitive to RSL3-induced ferroptosis. Cancer Res. 2021 Mar 15;81(6):1583-1594.
DU145 0.125, 0.25, 0.5, 1, 2, and 4 μM 72 h To evaluate the effect of RSL3 on prostate cancer cell growth, results showed that all prostate cancer cell lines were sensitive to RSL3-induced ferroptosis. Cancer Res. 2021 Mar 15;81(6):1583-1594.
G-361 0.5 µM 24 h RSL3 induced ferroptosis in G-361 cells, and overexpression of miR-137 suppressed RSL3-induced ferroptosis Cell Death Differ. 2018 Aug;25(8):1457-1472.
A375 0.1 µM 24 h RSL3 induced ferroptosis in A375 cells, and overexpression of miR-137 suppressed RSL3-induced ferroptosis Cell Death Differ. 2018 Aug;25(8):1457-1472.
HT29 cells 3 µM 24 h RSL3 induced ferroptosis by increasing ROS levels and the cellular labile iron pool, leading to cell death. Front Pharmacol. 2018 Nov 22;9:1371.
LoVo cells 3 µM 24 h RSL3 induced ferroptosis by increasing ROS levels and the cellular labile iron pool, leading to cell death. Front Pharmacol. 2018 Nov 22;9:1371.
HCT116 cells 3 µM 24 h RSL3 induced ferroptosis by increasing ROS levels and the cellular labile iron pool, leading to cell death. Front Pharmacol. 2018 Nov 22;9:1371.
PANC1 cells 0.5 µM 6 h RSL3 induced cell death and lipid peroxidation in PANC1 cells, and CQ inhibited RSL3-induced cell death and lipid peroxidation. Autophagy. 2021 Nov;17(11):3361-3374.
HT1080 cells 0.5 µM 6 h RSL3 induced cell death and lipid peroxidation in HT1080 cells, and CQ inhibited RSL3-induced cell death and lipid peroxidation. Autophagy. 2021 Nov;17(11):3361-3374.
60 human cancer cell lines 0.5 µM 3 and 6 h RSL3 exhibits wider and stronger activity in the upregulation of MAP1LC3B-II or downregulation of SQSTM1 in 80% (48/60) or 63% (38/60) of cell lines, respectively. Both RSL3 and erastin failed to affect SLC7A11 expression, but they led to GPX4 downregulation in 12% (7/60) and 3% (2/60) of cell lines, respectively. Autophagy. 2021 Nov;17(11):3361-3374.
SH-SY5Y cells 20 μM To evaluate the inhibitory effect of RSL3 and erastin-induced ferroptosis in SH-SY5Y cells, it was found that ThA increased cell viability in a dose-dependent manner at concentrations of 2-16 μM. Theranostics. 2024 Sep 23;14(16):6161-6184.
PC-12 cells 0.5 μM 4, 8, 12, 24 h To evaluate the inhibitory effect of RSL3-induced ferroptosis in PC-12 cells, it was found that ThA significantly increased cell survival and effectively prevented ferroptosis at all observed time points. Theranostics. 2024 Sep 23;14(16):6161-6184.
Huh7 5 μM RSL3 significantly suppressed the viability of Huh7 cells and induced ferroptosis. Drug Des Devel Ther. 2021 Sep 18;15:3965-3978.
HepG2 5 μM RSL3 significantly suppressed the viability of HepG2 cells and induced ferroptosis. Drug Des Devel Ther. 2021 Sep 18;15:3965-3978.
human epidermal keratinocytes (HEKa) 10 μM 6 h To assess the effect of RSL3 on cell viability, results showed that RSL3 treatment significantly reduced cell viability. J Clin Invest. 2024 Nov 21;135(2):e183219.
EOC 20 microglial cells 500 nM 5 h To test the sensitivity to RSL3-induced ferroptosis, M1-activated cells showed high resistance to RSL3, while M0 and M2-activated cells were susceptible. Nat Chem Biol. 2020 Mar;16(3):278-290.
Bone marrow-derived macrophages (BMDM) 500 nM 5 h To test the sensitivity to RSL3-induced ferroptosis, M1-activated cells showed high resistance to RSL3, while M0 and M2-activated cells were susceptible. Nat Chem Biol. 2020 Mar;16(3):278-290.
RAW 264.7 macrophages 500 nM 5 h To test the sensitivity to RSL3-induced ferroptosis, M1-activated cells showed high resistance to RSL3, while M0 and M2-activated cells were susceptible. Nat Chem Biol. 2020 Mar;16(3):278-290.
HK2 cells 1 μM 24 h RSL3 induces ferroptosis in HK2 cells, leading to increased lipid peroxidation and cell death. Redox Biol. 2023 Dec;68:102939.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
NSG (NOD-SCID-IL2R γ) male mice Prostate cancer xenograft model Intraperitoneal injection 100 mg/kg Twice per week, until the end of the experiment To evaluate the effect of RSL3 on tumor growth in prostate cancer xenograft models, results showed that RSL3 significantly delayed tumor growth of DU145 and PC3 xenografts. Cancer Res. 2021 Mar 15;81(6):1583-1594.
Nude mice Subcutaneous tumor model Intraperitoneal injection 15 mg/kg Twice every other day for 20 days Knockdown of miR-137 enhanced erastin-induced ferroptosis and inhibited tumor growth Cell Death Differ. 2018 Aug;25(8):1457-1472.
Mice C57BL/6 mice Topical application 10 μM (120 μL) Twice daily for 2 weeks To evaluate the effect of RSL3 on mouse skin, results showed that RSL3 increased ferroptosis-specific oxPE species in the epidermis but did not induce psoriasis-like epidermal changes or immune cell infiltration. J Clin Invest. 2024 Nov 21;135(2):e183219.
Mice Zymosan-induced peritonitis model Intraperitoneal injection 40 mg/kg Single injection, lasting 5 hours To test the effect of RSL3 on M2 macrophages in vivo, RSL3 significantly reduced the number of M2 macrophages, while the NO donor DETA NONOate suppressed this reduction. Nat Chem Biol. 2020 Mar;16(3):278-290.
Mice AKI-CKD model Intraperitoneal injection 5 mg/kg Daily for 14 days RSL3 pretreatment significantly increased renal fibrosis and ferroptosis in AKI-CKD model mice and abrogated the anti-ferroptosis and renoprotective effects of RGFP966. Redox Biol. 2023 Dec;68:102939.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.27mL

0.45mL

0.23mL

11.34mL

2.27mL

1.13mL

22.68mL

4.54mL

2.27mL

References

 

Historical Records

Categories